ADPT — Adaptive Biotechnologies Share Price
Last Trade - 00:00- $4.31bn
- $3.71bn
- $133.43m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 38.45 | 55.66 | 85.07 | 98.38 | 152.01 | 205.72 | 36.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
Directors
- Chad Robins (46)
- Julie Rubinstein (49)
- Harlan Robins (48)
- Chad Cohen (46)
- Mark Adams COO (54)
- Francis Lo (40)
- Stacy Taylor (61)
- Susan Bobulsky (40)
- Jyoti Palaniappan (46)
- Henning Thorsen (55)
- Lance Baldo (48)
- Sharon Benzeno OTH (47)
- Peter Neupert (65)
- Kevin Conroy (55)
- Michelle Griffin (55)
- Robert Hershberg (58)
- Katey Owen (52)
- Michael Pellini (55)
- Leslie Trigg (50)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- September 8th, 2009
- Public Since
- June 27th, 2019
- No. of Shareholders
- 117
- No. of Employees
- 622
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 140,765,849
- Address
- 1551 Eastlake Ave E Ste 200, SEATTLE, 98102-7402
- Web
- https://www.adaptivebiotech.com
- Phone
- +1 2066590067
- Contact
- Karina Calzadilla
- Auditors
- Ernst & Young LLP
Latest News for ADPT
Upcoming events for ADPT
Q3 2021 Adaptive Biotechnologies Corp Earnings Release
Similar to ADPT
GUARDANT HEALTH ORD
NASDAQ Global Select Market
FAQ
As of Today at 19:55 UTC, shares in Adaptive Biotechnologies are trading at $30.59. This share price information is delayed by 15 minutes.
Shares in Adaptive Biotechnologies last closed at $30.59 and the price had moved by -25.46% over the past 365 days. In terms of relative price strength the Adaptive Biotechnologies share price has underperformed the S&P500 Index by -43.45% over the past year.
The overall consensus recommendation for Adaptive Biotechnologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Adaptive Biotechnologies does not currently pay a dividend.
Adaptive Biotechnologies does not currently pay a dividend.
Adaptive Biotechnologies does not currently pay a dividend.
To buy shares in Adaptive Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $30.59, shares in Adaptive Biotechnologies had a market capitalisation of $4.31bn.
Here are the trading details for Adaptive Biotechnologies:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ADPT
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Adaptive Biotechnologies does not currently have a style classification.
The analyst consensus target price for shares in Adaptive Biotechnologies is $56.50. That is 84.7% above the last closing price of $30.59.
Analysts covering Adaptive Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -$1.54 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptive Biotechnologies. Over the past six months, its share price has underperformed the S&P500 Index by -56.37%.
As of the last closing price of $30.59, shares in Adaptive Biotechnologies were trading -33.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adaptive Biotechnologies.
Adaptive Biotechnologies' management team is headed by:
- Chad Robins -
- Julie Rubinstein -
- Harlan Robins -
- Chad Cohen -
- Mark Adams - COO
- Francis Lo -
- Stacy Taylor -
- Susan Bobulsky -
- Jyoti Palaniappan -
- Henning Thorsen -
- Lance Baldo -
- Sharon Benzeno - OTH
- Peter Neupert -
- Kevin Conroy -
- Michelle Griffin -
- Robert Hershberg -
- Katey Owen -
- Michael Pellini -
- Leslie Trigg -
We do not have data on Adaptive Biotechnologies' shareholders